CLINIMIX 5/20 SULFITE FREE IN DEXTROSE 20% IN PLASTIC CONTAINER Drug Patent Profile
When do Clinimix 5/20 Sulfite Free In Dextrose 20% In Plastic Container patents expire, and what generic alternatives are available?
Clinimix 5/20 Sulfite Free In Dextrose 20% In Plastic Container is a drug marketed by Baxter Hlthcare and is included in one NDA.
The generic ingredient in CLINIMIX 5/20 SULFITE FREE IN DEXTROSE 20% IN PLASTIC CONTAINER is amino acids; dextrose. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the amino acids; dextrose profile page.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for CLINIMIX 5/20 SULFITE FREE IN DEXTROSE 20% IN PLASTIC CONTAINER?
- What are the global sales for CLINIMIX 5/20 SULFITE FREE IN DEXTROSE 20% IN PLASTIC CONTAINER?
- What is Average Wholesale Price for CLINIMIX 5/20 SULFITE FREE IN DEXTROSE 20% IN PLASTIC CONTAINER?
Summary for CLINIMIX 5/20 SULFITE FREE IN DEXTROSE 20% IN PLASTIC CONTAINER
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| DailyMed Link: | CLINIMIX 5/20 SULFITE FREE IN DEXTROSE 20% IN PLASTIC CONTAINER at DailyMed |
Pharmacology for CLINIMIX 5/20 SULFITE FREE IN DEXTROSE 20% IN PLASTIC CONTAINER
| Drug Class | Amino Acid |
US Patents and Regulatory Information for CLINIMIX 5/20 SULFITE FREE IN DEXTROSE 20% IN PLASTIC CONTAINER
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baxter Hlthcare | CLINIMIX 5/20 SULFITE FREE IN DEXTROSE 20% IN PLASTIC CONTAINER | amino acids; dextrose | INJECTABLE;INJECTION | 020734-016 | Sep 29, 1997 | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
CLINIMIX 5/20 Sulfite-Free in Dextrose 20%: Market Dynamics, Patent Position, and Financial Trajectory
CLINIMIX 5/20 Sulfite Free in Dextrose 20% is a premixed parenteral nutrition product marketed by Baxter Healthcare. It contains 5% amino acids and 20% dextrose in a plastic container and is primarily used when adult patients require intravenous nutrition through a central venous catheter. The product is a mature, largely commoditized hospital injectable with limited product-level financial disclosure, low patent-driven entry risk, and demand tied more closely to hospital utilization, supply continuity, and manufacturing capacity than to exclusivity.
Baxter does not separately report CLINIMIX revenue. The product contributes to Baxter’s broader nutrition and injectable-product portfolio, which is reported within larger business segments. Its financial trajectory is therefore best assessed through hospital parenteral-nutrition demand, pricing, product availability, manufacturing resilience, and competition from other premixed formulations and compounded nutrition.
What is CLINIMIX 5/20 Sulfite Free in Dextrose 20%?
CLINIMIX 5/20 is a two-compartment intravenous nutrition formulation containing amino acids and dextrose. The compartments are mixed before administration, allowing the product to be stored separately until activation.
| Product characteristic | Description |
|---|---|
| Brand | CLINIMIX |
| Manufacturer | Baxter Healthcare Corporation |
| Formulation | 5% amino acids and 20% dextrose |
| Sulfite status | Sulfite-free |
| Container | Flexible plastic, dual-chamber container |
| Route | Intravenous infusion |
| Primary setting | Hospitals, intensive-care units, surgical units, and other acute-care facilities |
| Typical access | Central venous administration because of high osmolarity |
| Therapeutic category | Parenteral nutrition |
| Regulatory type | Conventional FDA-approved injectable drug product |
| Biosimilar status | Not applicable |
The product supplies nitrogen through amino acids and calories through dextrose. It does not provide a complete nutritional regimen by itself. Clinicians generally add electrolytes, vitamins, trace elements, and other components according to the patient’s clinical requirements and institutional protocols. The FDA labeling emphasizes individualized dosing and monitoring of glucose, electrolytes, fluid balance, renal function, and hepatic status.[1]
What is the FDA regulatory status of CLINIMIX 5/20?
CLINIMIX is an FDA-approved parenteral nutrition product associated with Baxter’s NDA 020505 product family and related supplements. The product is regulated as a conventional prescription injectable, not as a biologic.
The commercial significance of its regulatory status is limited because the product has been marketed for many years. It does not benefit from current-new-drug exclusivity. Its market position depends on manufacturing scale, hospital contracts, formulary placement, distribution reliability, and the ability to meet demand for sterile injectable nutrition products.
Does CLINIMIX 5/20 have pediatric exclusivity or orphan exclusivity?
No current pediatric, orphan, or other meaningful market exclusivity is associated with this mature product. Parenteral nutrition products can be clinically important for neonatal and pediatric care, but clinical importance does not create orphan-drug exclusivity unless the product independently satisfies the statutory requirements.
Is CLINIMIX 5/20 a biosimilar product?
No. Biosimilar regulation applies to biological products. CLINIMIX is a chemically defined amino-acid and dextrose injectable formulation. Competitive entry would occur through conventional drug approval, alternative premixed products, compounded parenteral nutrition, or hospital pharmacy preparation rather than through the biosimilar pathway.
What patents protect CLINIMIX 5/20?
The commercial patent position for CLINIMIX 5/20 is weak relative to newer specialty pharmaceuticals. The core ingredients, amino acids and dextrose, are longstanding pharmaceutical substances. The principal commercial protections historically associated with products of this type involve formulation design, container systems, manufacturing controls, and trade secrets rather than a blocking patent on the active ingredients.
| IP category | Relevance to CLINIMIX 5/20 |
|---|---|
| Active-ingredient patents | No meaningful current protection for amino acids or dextrose |
| New chemical entity exclusivity | Expired or inapplicable |
| Formulation patents | Potentially relevant historically, but unlikely to create material current exclusivity |
| Dual-chamber container technology | May be protected by legacy patents or manufacturing know-how |
| Sterility and filling processes | Primarily manufacturing know-how and regulatory capability |
| Method-of-use patents | No material product-specific barrier identified |
| Trademark | CLINIMIX brand protection remains commercially relevant |
| Trade secrets | Potentially important in container fabrication, filling, sterilization, and quality systems |
No current patent-based launch barrier is apparent from the product’s mature regulatory profile. Publicly available product information does not establish an active patent expiry date that would materially delay competing premixed amino-acid and dextrose products.
What is the Orange Book status of CLINIMIX 5/20?
CLINIMIX is not generally viewed as an Orange Book-driven product. The Orange Book can list patents and exclusivity for eligible approved drug products, but mature parenteral nutrition products typically compete without a significant patent listing strategy.
The relevant commercial distinction is between:
- A generic or therapeutically equivalent product approved against the same reference product.
- An alternative premixed parenteral nutrition formulation with different amino-acid, lipid, electrolyte, or dextrose composition.
- A pharmacy-compounded formulation prepared under hospital or outsourcing-pharmacy controls.
These categories do not create identical regulatory substitution rights. A competing premixed nutrition product may take share without being automatically substitutable at the pharmacy level.
When does CLINIMIX 5/20 lose exclusivity?
CLINIMIX 5/20 has no meaningful remaining period of market exclusivity comparable to a modern branded prescription drug. Its commercial exclusivity was effectively lost years ago through the maturity of the formulation, the expiration of legacy intellectual property, and the availability of alternative parenteral nutrition products.
The product’s residual brand value comes from:
- Baxter’s established hospital contracts.
- Clinician familiarity with the CLINIMIX product family.
- Existing pharmacy protocols.
- Product availability in multiple bag sizes and concentrations.
- Baxter’s manufacturing and distribution infrastructure.
- The cost and operational burden of changing validated nutrition procedures.
These factors can delay share loss even when patent protection is weak.
What formulations are protected by the CLINIMIX product family?
The CLINIMIX family includes different amino-acid and dextrose concentrations, including formulations designed for central or peripheral administration depending on osmolarity and clinical use. The 5/20 product is a high-dextrose formulation generally associated with central venous administration.
The product’s main technical differentiation is its dual-chamber container. Amino acids and dextrose remain separated during storage and are mixed before use. This design supports shelf stability and reduces some risks associated with hospital compounding, although it does not eliminate the need for additives or individualized nutritional management.
The commercial value of the container is operational rather than patent-driven. Hospitals may prefer ready-to-activate products because they can reduce compounding workload, standardize preparation, and lower exposure to pharmacy capacity constraints.
How does CLINIMIX 5/20 compare with competing products?
CLINIMIX competes across three segments: premixed amino-acid and dextrose products, premixed three-in-one parenteral nutrition products, and pharmacy-compounded nutrition.
| Segment | Representative products or providers | Competitive effect |
|---|---|---|
| Amino-acid/dextrose premixes | Baxter CLINIMIX and CLINIMIX E | Closest product-level competition |
| Three-in-one formulations | Fresenius Kabi Kabiven, PeriKabiven, and SMOFlipid-related nutrition products | Compete for broader nutrition protocols |
| Hospital compounding | In-house hospital pharmacies | Substitutes for premixed products where capacity exists |
| Outsourcing pharmacies | FDA-regulated outsourcing facilities and specialized compounders | Provide customized formulations and surge capacity |
| Individual components | Separate amino acids, dextrose, lipids, electrolytes, vitamins | Enable customized regimens but increase preparation complexity |
CLINIMIX’s strongest competitive advantage is simplicity. Its weakness is that it does not provide the lipid component and may require additional supplementation. Three-in-one products can reduce preparation steps but may carry different clinical, storage, compatibility, and formulary considerations.
Which companies are challenging Baxter in parenteral nutrition?
The most relevant competitor is Fresenius Kabi, which markets a broad parenteral nutrition portfolio, including Kabiven and related products. Hospital pharmacies and outsourcing compounders also exert competitive pressure, particularly during product shortages or when patients require individualized formulations.
Competition is regional. A product available in the United States may not have the same status, presentation, or commercial presence in Europe, Canada, or other markets. Local sterile-manufacturing capacity, tender awards, reimbursement rules, and hospital purchasing groups have a direct impact on market share.
What generic entry risks exist for CLINIMIX 5/20?
The generic-entry risk is high in principle but moderate in practical execution.
A competing manufacturer would face several barriers:
- Sterile injectable manufacturing capacity.
- Validation of a dual-chamber container.
- Container-closure integrity requirements.
- Stability data for the unmixed and activated product.
- Control of particulate matter, endotoxins, and sterility.
- Compatibility data for additives.
- Reliable production of large-volume hospital products.
- Hospital contracting and distribution requirements.
- Supply obligations during shortages.
These barriers do not support premium pricing indefinitely. They do, however, limit the number of manufacturers willing to enter a low-margin, high-compliance segment.
The most credible generic-entry scenarios are:
- A direct premixed competitor with the same amino-acid and dextrose profile.
- A therapeutically similar product with different concentrations.
- A hospital or outsourcing-pharmacy shift toward compounded nutrition.
- Substitution toward three-in-one nutrition bags.
A direct competitor would have the greatest effect on price. Compounded substitution would have a greater effect on volume and hospital workflow.
What patent litigation or Paragraph IV challenges affect CLINIMIX 5/20?
No significant current Paragraph IV litigation or patent settlement involving CLINIMIX 5/20 is apparent from the product’s mature market profile. Paragraph IV challenges are more common for newer small-molecule drugs with valuable Orange Book-listed patents. They are less commercially central for long-established parenteral nutrition products.
The principal legal risks are more likely to involve:
- Product liability.
- Manufacturing deviations.
- Contamination or sterility events.
- Labeling and pharmacovigilance.
- Contract disputes with hospitals or group purchasing organizations.
- Regulatory enforcement related to current good manufacturing practices.
What supply-chain risks affect CLINIMIX 5/20?
Supply reliability is a major value driver. Large-volume sterile injectables are vulnerable to disruptions involving manufacturing plants, raw-material suppliers, plastic containers, ports, and quality-control release.
The 2024 disruption at Baxter’s North Cove facility in North Carolina demonstrated the financial importance of sterile intravenous-product capacity. The disruption affected the broader U.S. hospital supply chain and prompted allocation measures and regulatory responses for certain intravenous products.[2][3] Even when a specific CLINIMIX presentation is not permanently discontinued, allocation or intermittent availability can shift demand to competing products and compounded nutrition.
For hospitals, the relevant purchasing criteria are often:
- Consistent allocation.
- Shelf life.
- Bag sizes.
- Product concentration.
- Additive compatibility.
- Delivery performance.
- Ability to support emergency demand.
- Availability of alternative products during shortages.
These criteria can preserve CLINIMIX volume despite weak patent protection.
What is the financial trajectory for CLINIMIX 5/20?
Product-level revenue, gross margin, unit volume, and operating profit are not separately disclosed by Baxter. The financial trajectory must therefore be inferred from the economics of the hospital nutrition market and Baxter’s broader reporting.
| Financial driver | Expected effect on CLINIMIX |
|---|---|
| Hospital admissions and critical-care volume | Supports baseline demand |
| Growth in home and long-term parenteral nutrition | Expands the broader nutrition market, though not all demand uses this product |
| Pricing pressure | Limits revenue growth in a mature formulation |
| Sterile manufacturing costs | Pressures margins |
| Plastic and packaging costs | Increases cost per bag |
| Supply disruptions | Can reduce sales, trigger allocation, or redirect demand |
| Contract renewals | Can materially affect volume and price |
| Product shortages among competitors | Can temporarily increase CLINIMIX demand |
| Customized compounding | Erodes premix volume in some institutions |
| Product discontinuation or line rationalization | Can improve portfolio economics but reduce access |
The likely financial profile is mature and defensive rather than growth-oriented. Revenue growth would more likely come from price, mix, hospital utilization, or supply-driven share gains than from new clinical indications. Margin performance depends on manufacturing efficiency and supply continuity because the formulation itself has limited pricing power.
How does CLINIMIX 5/20 compare with newer pharmaceutical products?
CLINIMIX has a low innovation premium and low exclusivity value. Its economics differ sharply from specialty drugs and biologics.
| Attribute | CLINIMIX 5/20 | Specialty drug or biologic |
|---|---|---|
| Patent dependence | Low | Often high |
| Market exclusivity | Minimal | Often central to valuation |
| Reimbursement | Hospital and institutional purchasing | Pharmacy, medical benefit, or specialty channels |
| Switching driver | Price, availability, protocol | Clinical differentiation and evidence |
| Regulatory risk | Sterility and manufacturing | Clinical, safety, immunogenicity, and manufacturing |
| Revenue disclosure | Aggregated within portfolio | Often reported by product |
| Generic or biosimilar exposure | Conventional product competition | Generic or biosimilar competition |
| Commercial life cycle | Long, mature, defensive | Defined by exclusivity and indication expansion |
For investment analysis, CLINIMIX should be modeled as a hospital supply-chain product rather than as an innovation-led branded pharmaceutical.
What is the geographic coverage of CLINIMIX 5/20?
Baxter has historically marketed CLINIMIX and related nutrition products across multiple healthcare markets, but presentation, labeling, regulatory approvals, and availability vary by country. The United States is strategically important because of its large hospital market and recurring shortages of sterile injectable products.
Geographic expansion is constrained by:
- National approval requirements.
- Local nutrition standards.
- Hospital tender systems.
- Reimbursement policies.
- Packaging and labeling rules.
- Local sterile-production capacity.
- Import and distribution controls.
A product’s presence in one jurisdiction does not establish approval or commercial availability in another.
How strong is the patent estate for CLINIMIX 5/20?
The patent estate is weak as a source of current exclusivity but potentially meaningful as a historical or manufacturing asset. The strongest defensible commercial elements are likely the brand, validated manufacturing process, container technology, regulatory file, and supply infrastructure.
A strategic acquirer would value the product for recurring institutional demand and manufacturing access, not for a long patent runway. A generic entrant would not need to overcome a major composition-of-matter patent, but it would need to build or contract compliant sterile manufacturing and establish hospital distribution.
Key Takeaways
- CLINIMIX 5/20 is a mature Baxter parenteral nutrition product containing 5% amino acids and 20% dextrose.
- The product has little current patent or regulatory exclusivity value.
- Biosimilar risk does not apply because CLINIMIX is not a biologic.
- Direct competition comes from Fresenius Kabi products, other premixed nutrition products, and hospital or outsourcing-pharmacy compounding.
- Product-level revenue and profitability are not publicly disclosed by Baxter.
- The financial profile is mature and supply-chain driven, with limited ability to sustain premium pricing.
- Sterile manufacturing, dual-chamber packaging, quality systems, and hospital contracts are more important barriers than patents.
- The largest near-term commercial risks are supply disruption, contract repricing, hospital compounding, and substitution by three-in-one nutrition products.
- No material current Paragraph IV litigation or patent settlement is apparent for the product.
- Baxter’s manufacturing continuity and hospital distribution remain the central determinants of CLINIMIX commercial performance.
FAQs About CLINIMIX 5/20 Sulfite Free
Is CLINIMIX 5/20 the same as total parenteral nutrition?
No. CLINIMIX supplies amino acids and dextrose but generally requires additional electrolytes, vitamins, trace elements, and sometimes lipid emulsion to create a complete individualized parenteral nutrition regimen.
Can CLINIMIX 5/20 be administered through a peripheral vein?
The 20% dextrose formulation has high osmolarity and is generally intended for central venous administration. The applicable FDA labeling and institutional protocol control the administration decision.[1]
Does CLINIMIX 5/20 contain sulfites?
The referenced presentation is identified as sulfite-free. This distinguishes it from certain amino-acid products that contain sulfite preservatives or excipients.
Who manufactures a competing product to CLINIMIX 5/20?
Fresenius Kabi is the principal large pharmaceutical competitor in parenteral nutrition. Hospitals, outsourcing facilities, and specialty compounding pharmacies also compete through customized formulations.
Is CLINIMIX 5/20 likely to be discontinued?
A discontinuation assessment requires a current manufacturer notice or FDA product-availability record. The product’s mature status makes portfolio rationalization possible, but demand, hospital contracts, and supply obligations support continued commercial relevance.
References
- U.S. Food and Drug Administration. (n.d.). CLINIMIX: Amino acids and dextrose injection prescribing information. Baxter Healthcare Corporation.
- U.S. Food and Drug Administration. (2024). FDA statement on supply of intravenous fluids and actions to address shortages following Hurricane Helene.
- Baxter International Inc. (2024). Annual report and regulatory filings.
- U.S. Food and Drug Administration. (n.d.). Drug shortages and product availability information.
- Fresenius Kabi USA. (n.d.). Parenteral nutrition products and prescribing information.
More… ↓
